Dikaia Xenaki

Dikaia Xenaki

Auto-generated profile, based on publicly available information

Dikaia Xenaki

Respiratory Cell and Molecular Biology Group, Woolcock Institute of Medical Research, Macquarie Park, NSW 2113, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Chemosphere
Verified
Journal Article
Closed access
BWBaoming Wang
Baoming Wang
Hui ChenHui Chen
Hui Chen
DXDia Xenaki
Dia Xenaki
JLJiayan Liao
Jiayan Liao
CCChristine Cowie
Christine Cowie
Brian G. OliverBrian G. Oliver
Brian G. Oliver

9 March 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
VKVinod Kumar Kannaujiya
Vinod Kumar Kannaujiya
GRGabriele De Rubis
Gabriele De Rubis
KPKeshav Raj Paudel
Keshav Raj Paudel
BMBikash Manandhar
Bikash Manandhar
DCDinesh Kumar Chellappan
Dinesh Kumar Chellappan
Kamal DuaKamal Dua
Kamal Dua

1 April 2017 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Open access
BPBrijeshkumar S Patel
Brijeshkumar S Patel
MRMostafizur Rahman
Mostafizur Rahman
GBGina Baehring
Gina Baehring
DXDikaia Xenaki
Dikaia Xenaki
FTFrancesca Su-May Tang
Francesca Su-May Tang
AAAlaina J. Ammit
Alaina J. Ammit
Roflumilast is an orally active phosphodiesterase 4 inhibitor approved for use in chronic obstructive pulmonary disease. Roflumilast N-oxide (RNO) is the active metabolite of roflumilast and has a demonstrated antiinflammatory impact in vivo and in vitro. To date, the effect of RNO on the synthetic function of airway smooth muscle (ASM) cells is unknown. We address this herein and investigate the effect of RNO on β2-adrenoceptor-mediated, cAMP-dependent responses in ASM cells in vitro, and whether RNO enhances steroid-induced repression of inflammation. RNO (0.001–1,000 nM) alone had no effect on AMP production from ASM cells, and significant potentiation of the long-acting β2-agonist formoterol-induced cAMP could only be achieved at the highest concentration of RNO tested (1,000 nM). At this concentration, RNO exerted a small, but not significantly different, potentiation of formoterol-induced expression of antiinflammatory mitogen-activated protein kinase phosphatase 1. Consequently, tumor necrosis factor–induced IL-8 secretion was unaffected by RNO in combination with formoterol. However, because there was the potential for phosphodiesterase 4 inhibitors and long-acting β2-agonists to interact with corticosteroids to achieve superior antiinflammatory efficacy, we examined whether RNO, alone or in combination with formoterol, enhanced the antiinflammatory effect of dexamethasone by measuring the impact on IL-8 secretion. Although RNO alone did not significantly enhance the cytokine repression achieved with steroids, RNO in combination with formoterol significantly enhanced the antiinflammatory effect of dexamethasone in ASM cells. This was linked to increased mitogen-activated protein kinase phosphatase 1 expression in ASM cells, suggesting that a molecular mechanism is responsible for augmented antiinflammatory actions of combination therapeutic approaches that include RNO.

30 May 2020 in Physiological Reports
Verified
Journal Article
Open access
KRKarosham Diren Reddy
Karosham Diren Reddy
SRSandra Rutting
Sandra Rutting
KTKatrina Tonga
Katrina Tonga
DXDikaia Xenaki
Dikaia Xenaki
JSJodie L. Simpson
Jodie L. Simpson
Brian G. OliverBrian G. Oliver
Brian G. Oliver
Diverging susceptibility and severity in respiratory diseases is prevalent between males and females. Sex hormones have inconclusively been attributed as the cause of these differences, however, strong evidence exists promoting genetic factors leading to sexual dimorphism. As such, we investigate differential proinflammatory cytokine (interleukin (IL)-6 and CXCL8) release from TNF-α stimulated primary human lung fibroblasts in vitro. We present, for the first time, in vitro evidence supporting clinical findings of differential production of IL-6 between males and females across various respiratory diseases. IL-6 was found to be produced approximately two times more from fibroblasts derived from females compared to males. As such we demonstrate sexual dimorphism in cytokine production of IL-6 outside the context of biological factors in the human body. As such, our data highlight that differences exist between males and females in the absence of sex hormones. We, for the first time, demonstrate inherent in vitro differences exist between males and females in pulmonary fibroblasts.

18 February 2021 in Nanomedicine
Verified
Journal Article
Closed access
MMMeenu Mehta
Meenu Mehta
Keshav Raj PaudelKeshav Raj Paudel
Keshav Raj Paudel
NPNisha Panth
Nisha Panth
DXDikaia Xenaki
Dikaia Xenaki
Ronan MacLoughlinRonan MacLoughlin
Ronan MacLoughlin
Kamal DuaKamal Dua
Kamal Dua